Paulette D Chandler1, Yiqing Song2, Jennifer Lin3, Shumin Zhang3, Howard D Sesso4, Samia Mora5, Edward L Giovannucci6, Kathryn E Rexrode7, M Vinayaga Moorthy8, Chunying Li8, Paul M Ridker5, I-Min Lee4, JoAnn E Manson4, Julie E Buring4, Lu Wang4. 1. Division of Preventive Medicine, Harvard Medical School, Boston, MA; pchandler@partners.org. 2. Department of Epidemiology, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN; 3. Takeda Pharmaceutical International Inc., Deerfield, IL; and. 4. Division of Preventive Medicine, Harvard Medical School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA. 5. Division of Preventive Medicine, Cardiovascular Division, and Harvard Medical School, Boston, MA; 6. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA. 7. Division of Preventive Medicine, Harvard Medical School, Boston, MA; 8. Division of Preventive Medicine.
Abstract
BACKGROUND: Lipid biomarkers, such as HDL-cholesterol concentrations, have been shown to have positive, inverse, and null associations with total, breast, and colorectal cancer risks. Studies of novel lipid biomarkers, such as apolipoprotein A-I (apo A-I) and apolipoprotein B-100 (apo B-100), and cancer risk have been sparse, to our knowledge. OBJECTIVES: We evaluated the prospective association of total, breast, colorectal, and lung cancers and cancer mortality with circulating lipid biomarkers in 15,602 female health professionals in the Women's Health Study (aged ≥45 y, free of cardiovascular disease and cancer, and without hormone replacement therapy or lipid-lowering medications at baseline). DESIGN: Cox regression models estimated HRs of cancer endpoints (19 y median follow-up) across quartiles 1 (reference) to 4 of each lipid biomarker after adjustment for cancer risk factors. RESULTS: Confirmed cases included 2163 incident cancer cases (864 breast, 198 colorectal, and 190 lung cancers) and 647 cancer deaths. Total cancer risk was significantly lower in the highest quartile of apo A-I (adjusted HR: 0.79; 95% CI: 0.70, 0.90; P-trend = 0.0008) and HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend = 0.01). For site-specific cancers, significant associations included colorectal cancer risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend = 0.03), triglycerides (HR: 1.86; 95% CI: 1.17, 2.97; P-trend = 0.02), and apo B-100 (HR: 1.60; 95% CI: 1.03, 2.49; P-trend = 0.006) and lung cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P-trend = 0.01). LDL cholesterol was not significantly associated with risk of total cancer or any site-specific cancers. In time-dependent models that were adjusted for the use of a lipid-lowering medication after baseline, these associations remained. CONCLUSIONS: Lipids were associated with total, lung, and colorectal cancer risks in women. Lifestyle interventions for heart-disease prevention, which reduce apo B-100 or raise HDL cholesterol, may be associated with reduced cancer risk. The Women's Health Study was registered at clinicaltrials.gov as NCT00000479.
BACKGROUND:Lipid biomarkers, such as HDL-cholesterol concentrations, have been shown to have positive, inverse, and null associations with total, breast, and colorectal cancer risks. Studies of novel lipid biomarkers, such as apolipoprotein A-I (apo A-I) and apolipoprotein B-100 (apo B-100), and cancer risk have been sparse, to our knowledge. OBJECTIVES: We evaluated the prospective association of total, breast, colorectal, and lung cancers and cancer mortality with circulating lipid biomarkers in 15,602 female health professionals in the Women's Health Study (aged ≥45 y, free of cardiovascular disease and cancer, and without hormone replacement therapy or lipid-lowering medications at baseline). DESIGN: Cox regression models estimated HRs of cancer endpoints (19 y median follow-up) across quartiles 1 (reference) to 4 of each lipid biomarker after adjustment for cancer risk factors. RESULTS: Confirmed cases included 2163 incident cancer cases (864 breast, 198 colorectal, and 190 lung cancers) and 647 cancer deaths. Total cancer risk was significantly lower in the highest quartile of apo A-I (adjusted HR: 0.79; 95% CI: 0.70, 0.90; P-trend = 0.0008) and HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend = 0.01). For site-specific cancers, significant associations included colorectal cancer risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend = 0.03), triglycerides (HR: 1.86; 95% CI: 1.17, 2.97; P-trend = 0.02), and apo B-100 (HR: 1.60; 95% CI: 1.03, 2.49; P-trend = 0.006) and lung cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P-trend = 0.01). LDL cholesterol was not significantly associated with risk of total cancer or any site-specific cancers. In time-dependent models that were adjusted for the use of a lipid-lowering medication after baseline, these associations remained. CONCLUSIONS:Lipids were associated with total, lung, and colorectal cancer risks in women. Lifestyle interventions for heart-disease prevention, which reduce apo B-100 or raise HDL cholesterol, may be associated with reduced cancer risk. The Women's Health Study was registered at clinicaltrials.gov as NCT00000479.
Authors: Ramon Estruch; Miguel Angel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Valentina Ruiz-Gutiérrez; María Isabel Covas; Miguel Fiol; Enrique Gómez-Gracia; Mari Carmen López-Sabater; Ernest Vinyoles; Fernando Arós; Manuel Conde; Carlos Lahoz; José Lapetra; Guillermo Sáez; Emilio Ros Journal: Ann Intern Med Date: 2006-07-04 Impact factor: 25.391
Authors: Esther K Wei; Edward Giovannucci; Charles S Fuchs; Walter C Willett; Christos S Mantzoros Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Rosa Reddavide; Giovanni Misciagna; Maria Gabriella Caruso; Maria Notarnicola; Raffaele Armentano; Maria Lucia Caruso; Michele Pirrelli; Anna Maria Valentini Journal: Anticancer Res Date: 2011-02 Impact factor: 2.480
Authors: W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1985-07 Impact factor: 4.897
Authors: S Salvini; D J Hunter; L Sampson; M J Stampfer; G A Colditz; B Rosner; W C Willett Journal: Int J Epidemiol Date: 1989-12 Impact factor: 7.196
Authors: Paulette D Chandler; Raji Balasubramanian; Nina Paynter; Franco Giulianini; Teresa Fung; Lesley F Tinker; Linda Snetselaar; Simin Liu; Charles Eaton; Deirdre K Tobias; Fred K Tabung; JoAnn E Manson; Edward L Giovannucci; Clary Clish; Kathryn M Rexrode Journal: Am J Clin Nutr Date: 2020-08-01 Impact factor: 7.045
Authors: Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas Journal: J Lipid Res Date: 2019-09-24 Impact factor: 5.922
Authors: Sara Lindström; Hilary Finucane; Brendan Bulik-Sullivan; Fredrick R Schumacher; Christopher I Amos; Rayjean J Hung; Kristin Rand; Stephen B Gruber; David Conti; Jennifer B Permuth; Hui-Yi Lin; Ellen L Goode; Thomas A Sellers; Laufey T Amundadottir; Rachael Stolzenberg-Solomon; Alison Klein; Gloria Petersen; Harvey Risch; Brian Wolpin; Li Hsu; Jeroen R Huyghe; Jenny Chang-Claude; Andrew Chan; Sonja Berndt; Rosalind Eeles; Douglas Easton; Christopher A Haiman; David J Hunter; Benjamin Neale; Alkes L Price; Peter Kraft Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-21 Impact factor: 4.254